ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Sanofi, Dr. Reddy's Laboratories and AstraZeneca side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

Sanofi×Dr. Reddy's Laboratories×AstraZeneca×Three at a time for now; Pro will compare up to ten.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

SanofiDr. Reddy's LaboratoriesAstraZeneca
studies on the registry2,4252494,197
open to participants now1057298
phase 3 studies under way610200
reach primary completion within a year664168
programswith a study of their own in two years81+12 named only4119+5 named only

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseSanofiDr. Reddy's LaboratoriesAstraZeneca
Phase 128%

Dr. Reddy's Laboratories: 3 of its 4 programs at phase 1

  1. AUR112phase 1
  2. DRL_ABphase 1
  3. CARD11-BCL10-MALT1 Complex Inhibitor XL114phase 1
75%

AstraZeneca: 25 of its 119 programs at phase 1

  1. AZD4954phase 1
  2. AZD1613phase 1
  3. AZD1390phase 1
  4. Actinium Ac 225-DOTA-Anti-STEAP2 Monoclonal Antibody AZD2284phase 1
  5. ALXN2230phase 1

and 20 more — sign in to see them all

21%
Phase 2

Sanofi: 25 of its 81 programs at phase 2

  1. brivekimigphase 2
  2. Acne mRNA vaccinephase 2
  3. Daxokafusp Alfaphase 2
  4. RSV+HMPV vaccinephase 2
  5. BLU-808phase 2

and 20 more — sign in to see them all

31%

Dr. Reddy's Laboratories: 1 of its 4 programs at phase 2

  1. CD47 Antagonist AUR103 Calciumphase 2
25%

AstraZeneca: 47 of its 119 programs at phase 2

  1. AZD9550phase 2
  2. zadavotide guraxetanphase 2
  3. palacaparibphase 2
  4. Berzanoflastphase 2
  5. AZD7798phase 2

and 42 more — sign in to see them all

39%
Phase 3

Sanofi: 22 of its 81 programs at phase 3

  1. rilzabrutinibphase 3
  2. frexalimabphase 3
  3. Pneumococcal 21-Valent Conjugate Vaccinephase 3
  4. lunsekimigphase 3
  5. duvakitugphase 3

and 17 more — sign in to see them all

27%
00%

AstraZeneca: 28 of its 119 programs at phase 3

  1. rilvegostomigphase 3
  2. datopotamab deruxtecanphase 3
  3. tremelimumabphase 3
  4. volrustomigphase 3
  5. Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012Fphase 3

and 23 more — sign in to see them all

24%
Approved, new studies

Sanofi: 11 of its 81 programs at approved, new studies

  1. dupilumabapproved, new study
  2. belumosudilapproved, new study
  3. sarilumabapproved, new study
  4. fitusiranapproved, new study
  5. Avapritinibapproved, new study

and 6 more — sign in to see them all

14%
00%

AstraZeneca: 19 of its 119 programs at approved, new studies

  1. durvalumabapproved, new study
  2. acalabrutinibapproved, new study
  3. trastuzumab deruxtecanapproved, new study
  4. osimertinibapproved, new study
  5. anifrolumabapproved, new study

and 14 more — sign in to see them all

16%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Sanofi30 readouts · 10 phase 3

Sanofi, Nov ’26: 3 programs whose next study reaches primary completion, 3 in phase 3

  1. rilzabrutinibphase 3 · Nov 25 · NCT07216079
  2. NVX-CoV2373 adjuvated lipid nanoparticleapproved, new study · Nov 26 · NCT07861542
  3. Measles, combinations with mumps and rubella, live attenuatedphase 3 · Nov 28 · NCT07103148

Sanofi, Dec ’26: 5 programs whose next study reaches primary completion, 1 in phase 3

  1. Pandemic flu H5 HA mRNA SD2 vaccinephase 2 · Dec 1 · NCT06907511
  2. Pneumococcal 21-Valent Conjugate Vaccinephase 3 · Dec 1 · NCT06838000
  3. brivekimigphase 2 · Dec 17 · NCT06958536
  4. frexalimabphase 3 · Dec 23 · NCT06500702
  5. BLU-808phase 2 · Dec 31 · NCT06931405

Sanofi, Jan ’27: 5 programs whose next study reaches primary completion, 1 in phase 3

  1. efanesoctocog alfaapproved, new study · Jan 15 · NCT04644575
  2. RSV+HMPV vaccinephase 2 · Jan 18 · NCT06686654
  3. Daxokafusp Alfaphase 2 · Jan 19 · NCT05584670
  4. belumosudilapproved, new study · Jan 26 · NCT07726914
  5. rF1V-1018phase 2 · Jan 29 · NCT07207408

Sanofi, Feb ’27: 2 programs whose next study reaches primary completion, 2 in phase 3

  1. dupilumabapproved, new study · Feb 7 · NCT07905547
  2. itepekimabphase 3 · Feb 17 · NCT07424144

Sanofi, Mar ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. fitusiranapproved, new study · Mar 25 · NCT05662319

Sanofi, Apr ’27: 6 programs whose next study reaches primary completion

  1. H5 Flu IMP 2phase 1 · Apr 4 · NCT07516418
  2. Inosine Monophosphatephase 1 · Apr 4 · NCT07516418
  3. RSV IMP 4phase 1 · Apr 4 · NCT07516418
  4. RSV IMP 5phase 1 · Apr 4 · NCT07516418
  5. RSV IMP 6phase 1 · Apr 4 · NCT07516418

and 1 more — sign in to see them all

Sanofi, May ’27: 1 program whose next study reaches primary completion

  1. SAR402663phase 2 · May 18 · NCT06660667

Sanofi, Jun ’27: 2 programs whose next study reaches primary completion

  1. lunsekimigphase 3 · Jun 21 · NCT06676319
  2. Avapritinibapproved, new study · Jun 23 · NCT03731260

Sanofi, Jul ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. riliprubartphase 3 · Jul 9 · NCT06290141

Sanofi, Aug ’27: 1 program whose next study reaches primary completion

  1. SAR448632phase 1 · Aug 15 · NCT07944885

Sanofi, Sep ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. zetrukibartphase 2 · Sep 22 · NCT07225569
  2. amlitelimabphase 3 · Sep 30 · NCT06241118

Sanofi, Oct ’27: 1 program whose next study reaches primary completion

  1. SAR446597phase 2 · Oct 13 · NCT07215234
Dr. Reddy's Laboratories2 readouts · 0 phase 3·

Dr. Reddy's Laboratories, Dec ’26: 1 program whose next study reaches primary completion

  1. DRL_ABphase 1 · Dec 29 · NCT07744828

Dr. Reddy's Laboratories, Jan ’27: 1 program whose next study reaches primary completion

  1. AUR112phase 1 · Jan 15 · NCT06755450
·········
AstraZeneca61 readouts · 16 phase 3

AstraZeneca, Nov ’26: 6 programs whose next study reaches primary completion

  1. elecoglipronphase 3 · Nov 18 · NCT07723833
  2. Elecoglipron Test formulation 1 Dose Aphase 1 · Nov 18 · NCT07723833
  3. Autologous dnTGF-BRII-armored Anti-STEAP2 CAR T-cells AZD0754phase 2 · Nov 24 · NCT06267729
  4. STEAP2-targeting Radioconjugate AZD2287phase 2 · Nov 24 · NCT06267729
  5. durvalumabapproved, new study · Nov 30 · NCT07081633

and 1 more — sign in to see them all

AstraZeneca, Dec ’26: 7 programs whose next study reaches primary completion, 2 in phase 3

  1. eculizumabapproved, new study · Dec 7 · NCT06724809
  2. AZD3974phase 1 · Dec 8 · NCT07290283
  3. baxdrostatphase 3 · Dec 10 · NCT07222917
  4. dapagliflozinapproved, new study · Dec 10 · NCT07222917
  5. benralizumabapproved, new study · Dec 23 · NCT05692180

and 2 more — sign in to see them all

AstraZeneca, Jan ’27: 12 programs whose next study reaches primary completion, 6 in phase 3

  1. laroprovstatphase 3 · Jan 4 · NCT07000136
  2. anifrolumabapproved, new study · Jan 6 · NCT05925803
  3. monalizumabphase 3 · Jan 8 · NCT05221840
  4. oleclumabphase 3 · Jan 8 · NCT05221840
  5. datopotamab deruxtecanphase 3 · Jan 11 · NCT06417814

and 7 more — sign in to see them all

AstraZeneca, Feb ’27: 7 programs whose next study reaches primary completion, 3 in phase 3

  1. Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012Fphase 3 · Feb 1 · NCT06530849
  2. trastuzumab deruxtecanapproved, new study · Feb 10 · NCT06271837
  3. Berzanoflastphase 2 · Feb 11 · NCT07215702
  4. acalabrutinibapproved, new study · Feb 15 · NCT02972840
  5. zibotentanphase 3 · Feb 18 · NCT06087835

and 2 more — sign in to see them all

AstraZeneca, Mar ’27: 4 programs whose next study reaches primary completion

  1. AZD7760phase 2 · Mar 8 · NCT06749457
  2. AZD4954phase 1 · Mar 17 · NCT07812077
  3. AZD0543phase 1 · Mar 24 · NCT07824622
  4. Anti-Claudin 18.2 Antibody-drug Conjugate AZD4360phase 2 · Mar 31 · NCT06921928

AstraZeneca, Apr ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. AZD1043phase 1 · Apr 9 · NCT07511205
  2. camizestrantphase 3 · Apr 20 · NCT05774951
  3. ombetoxabartphase 2 · Apr 20 · NCT07285213

AstraZeneca, May ’27: 5 programs whose next study reaches primary completion, 2 in phase 3

  1. rilvegostomigphase 3 · May 4 · NCT04379596
  2. Anti-CD20/Anti-CD3/Anti-CD8 Trispecific Antibody AZD5492phase 2 · May 5 · NCT06916806
  3. AZD1613phase 1 · May 22 · NCT07228364
  4. Budesonideapproved, new study · May 31 · NCT07073950
  5. formoterolapproved, new study · May 31 · NCT07073950

AstraZeneca, Jun ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. tozorakimabphase 3 · Jun 7 · NCT06932263
  2. ravulizumabapproved, new study · Jun 25 · NCT07308574
  3. Anti-GPC3 T Cell-engaging Antibody AZD9793phase 2 · Jun 30 · NCT06795022

AstraZeneca, Jul ’27: 3 programs whose next study reaches primary completion

  1. ALXN1920phase 2 · Jul 2 · NCT07157787
  2. AZD2389phase 2 · Jul 7 · NCT07610837
  3. SC rilvegostomig + rHuphase 1 · Jul 19 · NCT07161414

AstraZeneca, Aug ’27: 4 programs whose next study reaches primary completion

  1. ALXN2230phase 1 · Aug 9 · NCT07352423
  2. AZD0240phase 1 · Aug 30 · NCT06218914
  3. SC durvalumab + rHuphase 1 · Aug 30 · NCT07391670
  4. AZD6793phase 2 · Aug 31 · NCT07082738

AstraZeneca, Sep ’27: 2 programs whose next study reaches primary completion

  1. palacaparibphase 2 · Sep 29 · NCT05123482
  2. puxitatug samrotecanphase 3 · Sep 29 · NCT05123482

AstraZeneca, Oct ’27: 5 programs whose next study reaches primary completion, 1 in phase 3

  1. opemalirsenphase 2 · Oct 4 · NCT06824987
  2. cevolisiranphase 2 · Oct 11 · NCT06744647
  3. tarperprumigphase 2 · Oct 11 · NCT07160608
  4. torvutatug samrotecanphase 3 · Oct 15 · NCT07402915
  5. sodium zirconium cyclosilicateapproved, new study · Oct 30 · NCT07944378
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 21, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Sanofi

New programs 6

Reached a new phase 1

Study stopped 4

  • balinatunfibphase 2 · terminated Oct 22 · none of its studies left running“Business decision” · NCT07222189
  • balinatunfibphase 2 · terminated Oct 21 · none of its studies left running“Business decision” · NCT06867094
  • balinatunfibphase 2 · terminated Oct 13 · none of its studies left running“Business decision.” · NCT06637631
  • amlitelimabphase 2 · terminated Oct 2“Sponsor decision; the decision is not related to any safety concern.” · NCT06033833

Primary completion later 2

Dr. Reddy's Laboratories

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

AstraZeneca

New programs 2

Reached a new phase 1

Study stopped 0

None

Primary completion later 23

Where they overlap

Conditions where at least two of them have programs: 29 in all, the first 12 here. A program counts in each condition its studies name most.

ConditionSanofiDr. Reddy's LaboratoriesAstraZeneca
Stomach Neoplasmsall three · compare here

Sanofi in Stomach Neoplasms: 1 program

  1. Daxokafusp Alfaphase 2

Their studies: Sanofi’s studies of Stomach Neoplasms in search

Dr. Reddy's Laboratories in Stomach Neoplasms: 1 program

  1. CD47 Antagonist AUR103 Calciumphase 2

Their studies: Dr. Reddy's Laboratories’ studies of Stomach Neoplasms in search

Arthritis, Rheumatoidall three · compare here

Sanofi in Arthritis, Rheumatoid: 2 programs

  1. balinatunfibphase 2
  2. sarilumabapproved, new study

Their studies: Sanofi’s studies of Arthritis, Rheumatoid in search

Dr. Reddy's Laboratories in Arthritis, Rheumatoid: 1 program

  1. DRL_ABphase 1

Their studies: Dr. Reddy's Laboratories’ studies of Arthritis, Rheumatoid in search

AstraZeneca in Arthritis, Rheumatoid: 2 programs

  1. surovatamigphase 3
  2. AZD1163phase 2

Their studies: AstraZeneca’s studies of Arthritis, Rheumatoid in search

Carcinoma, Non-Small-Cell Lung2 of 3 · compare here

Sanofi in Carcinoma, Non-Small-Cell Lung: 2 programs

  1. Tadalafilphase 3
  2. Pan-KRAS Inhibitor BLU-924phase 2

Their studies: Sanofi’s studies of Carcinoma, Non-Small-Cell Lung in search

–

AstraZeneca in Carcinoma, Non-Small-Cell Lung: 18 programs

  1. rilvegostomigphase 3
  2. datopotamab deruxtecanphase 3
  3. tremelimumabphase 3
  4. volrustomigphase 3
  5. ceralasertibphase 3

and 13 more — sign in to see them all

Their studies: AstraZeneca’s studies of Carcinoma, Non-Small-Cell Lung in search

Asthma2 of 3 · compare here

Sanofi in Asthma: 5 programs

  1. lunsekimigphase 3
  2. duvakitugphase 3
  3. amlitelimabphase 3
  4. itepekimabphase 3
  5. dupilumabapproved, new study

Their studies: Sanofi’s studies of Asthma in search

–

AstraZeneca in Asthma: 10 programs

  1. tozorakimabphase 3
  2. BFF MDIphase 3
  3. GP MDIphase 3
  4. londamocitinibphase 2
  5. sunakimentphase 2

and 5 more — sign in to see them all

Their studies: AstraZeneca’s studies of Asthma in search

Influenza, Human2 of 3 · compare here–

AstraZeneca in Influenza, Human: 2 programs

  1. AZD4117phase 2
  2. AZD5315phase 2

Their studies: AstraZeneca’s studies of Influenza, Human in search

Pulmonary Disease, Chronic Obstructive2 of 3 · compare here

Sanofi in Pulmonary Disease, Chronic Obstructive: 3 programs

  1. lunsekimigphase 3
  2. itepekimabphase 3
  3. dupilumabapproved, new study

Their studies: Sanofi’s studies of Pulmonary Disease, Chronic Obstructive in search

–

AstraZeneca in Pulmonary Disease, Chronic Obstructive: 8 programs

  1. tozorakimabphase 3
  2. GP MDIphase 3
  3. AZD6793phase 2
  4. Treatment A: BGF MDI HFOphase 1
  5. tezepelumabapproved, new study

and 3 more — sign in to see them all

Their studies: AstraZeneca’s studies of Pulmonary Disease, Chronic Obstructive in search

Respiratory Syncytial Virus Infections2 of 3 · compare here

Sanofi in Respiratory Syncytial Virus Infections: 9 programs

  1. RSVt Vaccinephase 3
  2. RSV+HMPV vaccinephase 2
  3. RSV vaccine formulation 1 dosephase 2
  4. H5 Flu IMP 2phase 1
  5. Inosine Monophosphatephase 1

and 4 more — sign in to see them all

Their studies: Sanofi’s studies of Respiratory Syncytial Virus Infections in search

–

AstraZeneca in Respiratory Syncytial Virus Infections: 1 program

  1. Palivizumabapproved, new study

Their studies: AstraZeneca’s studies of Respiratory Syncytial Virus Infections in search

Neoplasms2 of 3 · compare here–

Dr. Reddy's Laboratories in Neoplasms: 1 program

  1. CD47 Antagonist AUR103 Calciumphase 2

Their studies: Dr. Reddy's Laboratories’ studies of Neoplasms in search

AstraZeneca in Neoplasms: 6 programs

  1. saruparibphase 3
  2. ceralasertibphase 3
  3. Leucovorinphase 2
  4. Ramucirumabphase 2
  5. AZD1390phase 1

and 1 more — sign in to see them all

Their studies: AstraZeneca’s studies of Neoplasms in search

Dermatitis, Atopic2 of 3 · compare here

Sanofi in Dermatitis, Atopic: 5 programs

  1. lunsekimigphase 3
  2. amlitelimabphase 3
  3. itepekimabphase 3
  4. Dupilumab coformulated with berahyaluronidase alfaphase 3
  5. dupilumabapproved, new study

Their studies: Sanofi’s studies of Dermatitis, Atopic in search

–

AstraZeneca in Dermatitis, Atopic: 1 program

  1. tezepelumabapproved, new study

Their studies: AstraZeneca’s studies of Dermatitis, Atopic in search

Diabetes Mellitus, Type 22 of 3 · compare here

Sanofi in Diabetes Mellitus, Type 2: 1 program

  1. iGlarLixi (insulin glargine/lixisenatide)approved, new study

Their studies: Sanofi’s studies of Diabetes Mellitus, Type 2 in search

–

AstraZeneca in Diabetes Mellitus, Type 2: 5 programs

  1. elecoglipronphase 3
  2. lenbelintidephase 3
  3. AZD6793phase 2
  4. Elecoglipron Test formulation 1 Dose Aphase 1
  5. dapagliflozinapproved, new study

Their studies: AstraZeneca’s studies of Diabetes Mellitus, Type 2 in search

Diabetes Mellitus, Type 12 of 3 · compare here

Sanofi in Diabetes Mellitus, Type 1: 4 programs

  1. frexalimabphase 3
  2. brivekimigphase 2
  3. Biological Productsphase 1
  4. teplizumabapproved, new study

Their studies: Sanofi’s studies of Diabetes Mellitus, Type 1 in search

–

AstraZeneca in Diabetes Mellitus, Type 1: 1 program

  1. dapagliflozinapproved, new study

Their studies: AstraZeneca’s studies of Diabetes Mellitus, Type 1 in search

Lupus Erythematosus, Systemic2 of 3 · compare here

Sanofi in Lupus Erythematosus, Systemic: 2 programs

  1. frexalimabphase 3
  2. Anti-CD20 Bispecific Antibody DR-0201phase 1

Their studies: Sanofi’s studies of Lupus Erythematosus, Systemic in search

–

Show all 29

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

A target, or a pathogen for a vaccine, known for: Sanofi 54 of 81 · Dr. Reddy's Laboratories 2 of 4 · AstraZeneca 68 of 119 programs (41 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (Sanofi: 12, AstraZeneca: 5).